BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Full-Life Technologies Secures $571.5M Licensing Deal with SK Biopharmaceuticals for Anti-Cancer Radiopharmaceutical FL-091

Full-Life Technologies seals $571.5 million agreement with SK Biopharmaceuticals to license and further develop Full-Life's 'FL-091' ra...

September 19, 2024 | News

RSSL Introduces £700K Laboratory for Advanced 3D Imaging & Metrology Services

RSSL, a leading food and life science contract research organisation, has announced the opening of a new laboratory providing a suite of advanced 3D ...

September 19, 2024 | News

Bambusa Therapeutics Secures $15M in Series Seed Funding to Advance Bispecific Antibody Pipeline

Bambusa Therapeutics Inc., a biotechnology company focused on developing bispecific antibodies for the treatment of immunological and inflammatory (I&I...

September 10, 2024 | News

Arsenal Biosciences Closes $325 Million Series C Funding to Advance Next-Gen CAR T-Cell Therapies for Solid Tumors

Arsenal Biosciences, Inc. (ArsenalBio), a clinical stage programmable cell therapy company focused on engineering advanced CAR T-cell therapies for solid t...

September 05, 2024 | News

LOTTE Holdings Launches New CVC to Propel Innovations in Biopharmaceuticals and Next-Generation Modalities

LOTTE Holdings Co., Ltd. ("LOTTE Holdings") is pleased to announce the establishment of a new Healthcare and Biopharmaceutical Corporate Venture Capital ("...

August 29, 2024 | News

Finnish Biotech NADMED Secures €3.5M to Transform Vitamin B3 Testing with Groundbreaking NAD Measurement Technology

Finnish biotech company NADMED has developed the first test to measure all four bodily forms of vitamin B3, called NADs, and glutathiones directly from fre...

August 23, 2024 | News

Boston Immune Technologies and Therapeutics Secures Strategic Agreement with Otsuka's MSRD and $4M NIH/NCI Grant for Advancing Antibody Development

Boston Immune Technologies and Therapeutics, Inc. (BITT), a clinical stage developer of novel tumor necrosis factor superfamily receptor (TNFSR) antagonist...

August 19, 2024 | News

Rona Therapeutics Secures $35 Million Series A+ Financing to Advance siRNA Programs

Rona Therapeutics, a clinical stage pioneering platform company in nucleic acid drug research and development, today announced the completion of $35 M...

July 22, 2024 | News

Merck Group Announces Acquisition of UnitySC for €155 Million

This strategic acquisition is a significant milestone in Merck’s Electronics business, aimed at expanding its capabilities and strengthening ...

July 18, 2024 | News

Jubilant Radiopharma Invests $50 Million to Expand PET Radiopharmaceutical Manufacturing Facilities in the U.S.

Jubilant Radiopharma’s Radiopharmacies division is excited to announce an investment of $50 million (USD) to expand its PET radiopharmaceutical manuf...

June 25, 2024 | News

Ascentage Pharma Announces Completion of Equity Investment by Takeda

Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related...

June 21, 2024 | News

HanAll Biopharma Secures Exclusive Rights to Cutting-Edge Aging Reprogramming Technology

Exclusive agreement allows HanAll to utilize Epigenetic Reprogramming of Aging (ERATM) technology for ophthalmic and otic diseases. Collaboration aims t...

May 29, 2024 | News

AstraZeneca Announces $1.5 Billion Manufacturing Facility in Singapore for Cutting-Edge Cancer Treatments

AstraZeneca intends to build a $1.5 billion manufacturing facility in Singapore for antibody drug conjugates (ADCs), enhancing global s...

May 20, 2024 | News

Nabla Bio Secures $26 Million Series A and $550 Million in Strategic Pharma Collaborations

➢ Company builds integrated AI and wet lab technologies to design developable, selective, and functionally active protein drugs against ...

May 15, 2024 | News

Stay Connected